Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.

Mutation research - 3 Jun 2005

Dervieux Thierry, Meshkin Brian, Neri Bruce

Abstract excerpt

Several proofs of principle have established that pharmacogenetic testing for mutations altering expression and functions of genes associated with drug disposition and response can decrease the "trial-and-error" dosing and reduce the risk of adverse drug reactions. These proofs of principle include thiopurine methyltransferase and thiopurine therapy, dihydropyrimidine dehydrogenase/thymidylate synthase and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 Enzyme System
Share to Dideoxynucleosides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Testing

Share to Mutation

Share to Neoplasms

Share to Pharmacogenetics

Share to Warfarin

Source

Identifiers

PMID: 15829247
DOI: 10.1016/j.mrfmmm.2004.07.025

Genes

MTHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.PMID 15829247Read ↗

Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Semantic proximity Read ↗

Recommendations for pharmacogenetic testing in clinical practice guidelines in the USSemantic proximity Read ↗

Pharmacogenetic Testing: Time for Clinical Practice GuidelinesSemantic proximity Read ↗

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Semantic proximity Read ↗

Pharmacogenetic Markers of Drug Efficacy and Toxicity.Semantic proximity Read ↗

Pharmacogenetics of Adverse Drug Reactions.Semantic proximity Read ↗

Pharmacogenetics: transforming clinical medicine.Semantic proximity Read ↗

Practical Recommendations for Pharmacogenomics-based Prescription: 2010 ESF–UB Conference on Pharmacogenetics and PharmacogenomicsSemantic proximity Read ↗

Pharmacogenetic screening and therapeutic drugs.Semantic proximity Read ↗

Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkSemantic proximity Read ↗

Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era.Semantic proximity Read ↗

Economic evaluation of pharmacogenetic tests.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.